MedTrace Logo

A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

NCT07110883 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-08-08

No results posted yet for this study

Summary

This is an open-label, dose-escalation and cohort-expansion, multicenter Phase I study involving participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SYS6023

SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.

Sponsors & Collaborators

  • CSPC Megalith Biopharmaceutical Co.,Ltd.

    lead INDUSTRY

Principal Investigators

  • Shun Lu, M.D. · Shanghai Chest Hospital

  • Qingyuan Zhang, M.D. · Affiliated Tumor Hospital of Harbin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2026-10-31
Completion
2028-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07110883 on ClinicalTrials.gov